Top Section/Ad
Top Section/Ad
Most recent
M&A could be much needed shot in the arm but dollars expected to dominate
Deal includes $1bn 3.75 year term loan
The German pharmaceutical wholesaler was upgraded to BBB- by S&P last month
US drug company Eli Lilly jolted the dollar market awake on Wednesday with an eight-part jumbo trade to fund two recent acquisitions
More articles/Ad
More articles/Ad
More articles
-
Keymed Biosciences has started laying the groundwork for a planned Hong Kong IPO by filing its initial listing documents with the city’s exchange. -
A group of institutional investors owning international bonds issued by Suriname have agreed to grant the South American sovereign a third debt payment standstill after the issuer modified the terms of a consent solicitation.
-
An uneven economic recovery is expected across emerging and developed markets over the next year, the IMF said this week during its spring meetings. Meanwhile, a proposed boost to special drawing rights has split market opinion.
-
The announcement this week that the IMF is on its way to issuing a further $650bn of special drawing rights, providing central banks with extra foreign currency liquidity, should not be criticised for being too little, too late. It marks a much needed return to multilateralism, something that the developing world will benefit from.
-
Organon, the spin-off from US pharma company Merck, has launched a bond leg of its financing, which will establish the unit as a separate firm with its own capital structure, while funding a $9bn dividend to its former parent. The firm was initially offering $4.5bn-equivalent across secured and unsecured bonds, with a bias to the deeper dollar market, but scaled this up during syndication to allow it to strip out bank debt.
-
We Doctor Holdings, which operates Chinese healthcare platform WeDoctor, is seeking approval for a Hong Kong IPO.
